Chemomab Therapeutics Ltd.
CMMB
$1.23
$0.000.00%
NASDAQ
| 06/30/2023 | 03/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 46.85% | -21.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.44% | 4.71% | |||
| Operating Income | 9.44% | -4.71% | |||
| Income Before Tax | 9.12% | -5.69% | |||
| Income Tax Expenses | 61.90% | 110.00% | |||
| Earnings from Continuing Operations | 8.95% | -5.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 8.95% | -5.81% | |||
| EBIT | 9.44% | -4.71% | |||
| EBITDA | 9.45% | -4.69% | |||
| EPS Basic | 9.22% | -7.87% | |||
| Normalized Basic EPS | 9.39% | -7.74% | |||
| EPS Diluted | 9.22% | -7.87% | |||
| Normalized Diluted EPS | 9.39% | -7.74% | |||
| Average Basic Shares Outstanding | 0.31% | -1.91% | |||
| Average Diluted Shares Outstanding | 0.31% | -1.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||